News & Events

Pneumagen Raises £3.8 million to Advance the Phase II Clinical Development of Neumifil, a Pan-antiviral, Intranasal Drug for the Prophylaxis and Treatment of Viral Respiratory Tract Infections (RTIs)

Pneumagen initiates Phase 1 trial of Neumifil, a novel, intranasal pan anti-viral therapeutic for the prophylaxis and treatment of viral Respiratory Tract Infections

Pneumagen Appoints New Head of Research to Expand its Anti-Viral Pipeline leveraging its Proprietary GlycoTarge™ Platform

Pneumagen Announces Neumifil™ is Efficacious In an Established Model of COVID-19 Infection

Pneumagen Announces £2.5m fundraising to advance universal treatment for viral respiratory infections into the clinic this year

Pneumagen’s Neumifil for combating COVID-19 featured in SCRIP’s 10 to watch at BIO-Europe Digital

Pneumagen Announces Scientific Advisory Board and Development Team Appointments

Pneumagen Announces £4m fundraising and Commits to Clinical Trial Development for COVID-19

Pneumagen Ltd’s Recent COVID-19 Data Covered by BBC’s “The Nine”